Bio, I believe that Dr. Stupp's failure to mention the beneficial effect of DCVax-L for rGBM patients was no accident because that would have been the weakest point in his argument.
Deducting the 81 treatment patients alive at 24 months from randomization (NYAS presentation) from about 129-132 patients alive in the entire trial at 27 months from surgery (24 months from randomization, 2018 JTM article, fig. 1), we have about 48-51 living patients at 24 months who were in the combined group of 99 patients (65 crossovers and initially 35 non-DCVax-L treated patients.) Since Dr. Liau in her recent webinar stated that 7 of the 35 never treated patients dropped out, we are left with 64 crossovers and 29 never L treated patients. Since Dr. Liau also stated in the webinar that most of the 29 who were never treated with DCVax-L did rather poorly, it is a no brainer to conclude that at 24 months, of the 92 remaining patients in that last group, about 48-51 were alive and about 41-44 were deceased and that very few of the 48-51 survivors were never L treated patients and therefore the overwhelming majority of those 48-51 were crossovers.
This suggests that the mOS of the crossovers is well in excess of 24 months from randomization and that can only be attributed to DCVax-L treatment at progression and cannot be due to cherry picking or any other trial manipulation. It therefore makes sense for Dr. Stupp not to mention the rGBM results.
Bullish
Market Data 
Markets 
